

AdnaGen® Announces the Submission of a Request for a Pre-IDE Determination Meeting with FDA for AdnaGen's *AdnaTest Breast Cancer* for the Detection of Circulating Breast Tumor Cells

Langenhagen, Germany, May 7, 2008 – AdnaGen, a German company - of which 85% are owned by OncoVista Innovative Therapies Inc. (OTC BB: OVIT.OB) - engaged in the development and commercialization of proprietary diagnostics for the detection and molecular analysis of circulating tumor cells - announced the submission of a request to the U.S. Food and Drug Administration for a pre-IDE determination meeting for the AdnaGen *AdnaTest BreastCancer* for the detection of circulating breast tumor cells.

AdnaGen's CEO Dr. Wolfram Rodatz stated: "We are very delighted with the submission and looking forward to meeting with the FDA. It is the first important step towards a successful market development for AdnaGen's *AdnaTest BreastCancer* in the United States, the largest accessible market in the industrialized world."

AdnaGen's Managing Director, Dr. Winfried Albert, remarked: "We are very privileged to be able to work together with some of the foremost clinical research establishments in the USA and Europe towards a FDA approval of our innovative products already marketed in Europe. Hopefully, the patients in the United States too will be soon able to benefit from such an approval."

OncoVista's Chief Executive Officer, Alexander L. Weis, Ph.D., commented: "We are very pleased to have submitted this package to the FDA. The *AdnaTest* is intended for use as a prognostic test for women with metastatic breast cancer, in whom the presence of circulating tumor cells is associated with decreased progression-free survival and decreased overall survival and as such can be of tremendous benefit in determining those patients who can best benefit from a certain line of chemotherapy treatment. We are looking forward to working with the FDA to reach agreement on the design and evaluation criteria for a pivotal study for FDA approval for marketing the *AdnaTest* system in the United States."

About AdnaGen AG

AdnaGen, founded in 1999, is a privately held biotechnology research and development company based in Langenhagen, Germany. AdnaGen focuses on the development of innovative tumor diagnostics by utilizing its proprietary technology for the detection and molecular analysis of rare but clinically important cells. Kits for breast and colon cancer are CE-marked and currently marketed in Europe. AdnaGen is ISO 9001 and EN 13485 certified. For more information, go to www.adnagen.com.

About OncoVista, Inc.

OncoVista, based in San Antonio, TX, is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends to identify, develop and

rapidly commercialize innovative therapies for safer and more efficacious treatment of cancer. OncoVista's primary therapeutic strategy is based on targeting the patient's tumor(s) with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The company is utilizing the AdnaGen technology to drive its efforts to develop and bring to market more effective and less toxic drugs for treatment of cancer. For more information, go to www.oncovista.com.

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. Prospective investors should be aware that these statements reflect only the judgements and projections of AdnaGen's and OncoVista's management, and no undue reliance should be placed on such forward looking statements.